COMMUNIQUÉS West-GlobeNewswire
-
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
02/06/2026 -
Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies
02/06/2026 -
Augustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific Sessions
02/06/2026 -
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
02/06/2026 -
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
02/06/2026 -
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
02/06/2026 -
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
02/06/2026 -
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
02/06/2026 -
SEED Therapeutics Highlights Clinical Advancement and Broad Oncology Potential of ST-01156, an RBM39 Molecular Glue Degrader in First-in-Human in Phase 1 Studies, at ASCO 2026
02/06/2026 -
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
02/06/2026 -
Telix and United Imaging Announce Strategic Theranostics Collaboration
02/06/2026 -
Lumexa Imaging Announces Joint Venture with Hospital for Special Surgery (HSS) to Expand Advanced Outpatient Imaging in New York
02/06/2026 -
Soleo Health Acquires Realo Specialty Care Pharmacy and BluHaven Management, Expanding Footprint in Mid-Atlantic Region
02/06/2026 -
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
02/06/2026 -
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
02/06/2026 -
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
02/06/2026 -
FDA Grants Fast Track Designation to Merakris’ MTX-001, Opening Potential Accelerated Path to Market for Venous Leg Ulcer Therapy
02/06/2026 -
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
02/06/2026 -
The Ensign Group Acquires Real Estate and Operations in Iowa
02/06/2026
Pages